➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Harvard Business School
Merck
Express Scripts
Boehringer Ingelheim

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Patent: 9,486,475

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,486,475
Title:PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
Abstract: The present invention relates to a pentosanpolysulfate (PPS) or a pharmaceutically acceptable salt thereof for use in the amelioration, treatment, or prevention of adverse neurological events caused by administering an antibody or fragment thereof comprising a CD3 binding domain, including a CD19 x CD3 bispecific single chain antibody, such as blinatumomab. PPS is a semi-synthetically produced heparin-like macromolecular carbohydrate derivative, which chemically and structurally resembles glycosaminoglycans. Kits comprising a PPS, an antibody or fragment thereof comprising a CD3 binding domain, and instructions for administration, which indicate that the PPS is to be employed for the amelioration, treatment or prevention of adverse neurological events caused by administering the antibody or fragment thereof comprising said CD3 binding domain, are also disclosed.
Inventor(s): Kufer; Peter (Munich, DE), Nagorsen; Dirk (Munich, DE), Scheele; Juergen (Munich, DE), Zugmaier; Gerhard (Munich, DE), Klinger; Matthias (Gilching, DE), Hoffmann; Patrick (Bad Heilbrunn, DE), Naegele; Virginie (Munich, DE), Dopfer; Elaine-Pashupati (Munich, DE)
Assignee: AMGEN RESEARCH (MUNICH) GMBH (Munich, DE)
Application Number:14/176,089
Patent Claims:see list of patent claims

Details for Patent 9,486,475

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen BLINCYTO blinatumomab INJECTABLE;INJECTION 125557 001 2014-12-03   Start Trial AMGEN RESEARCH (MUNICH) GMBH (Munich, DE) 2033-02-08 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Medtronic
Harvard Business School
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.